{ "@context": "https://schema.org", "@type": "Organization", "name": "Brainscape", "url": "https://www.brainscape.com/", "logo": "https://www.brainscape.com/pks/images/cms/public-views/shared/Brainscape-logo-c4e172b280b4616f7fda.svg", "sameAs": [ "https://www.facebook.com/Brainscape", "https://x.com/brainscape", "https://www.linkedin.com/company/brainscape", "https://www.instagram.com/brainscape/", "https://www.tiktok.com/@brainscapeu", "https://www.pinterest.com/brainscape/", "https://www.youtube.com/@BrainscapeNY" ], "contactPoint": { "@type": "ContactPoint", "telephone": "(929) 334-4005", "contactType": "customer service", "availableLanguage": ["English"] }, "founder": { "@type": "Person", "name": "Andrew Cohen" }, "description": "Brainscape’s spaced repetition system is proven to DOUBLE learning results! Find, make, and study flashcards online or in our mobile app. Serious learners only.", "address": { "@type": "PostalAddress", "streetAddress": "159 W 25th St, Ste 517", "addressLocality": "New York", "addressRegion": "NY", "postalCode": "10001", "addressCountry": "USA" } }

Primary HPT Flashcards

(42 cards)

1
Q

The three pathologic conditions that result in primary HPT are

A

parathyroid adenoma&raquo_space; 85% to 90%
hyperplasia&raquo_space; 4% to 33%
carcinoma&raquo_space; less than 1% of cases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How to define multigland disease

A
  • multigland disease has been defined as persistent elevation of IOPTH levels despite the removal of a single hypersecreting parathyroid gland or persistent postoperative HPT after removal of a single parathyroid gland
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Risk factors for HPT

A
  • Exposure to ionizing radiation in the cervical region
  • nuclear accidents and radioactive iodine ablation for thyroid disease
    (latency period is approximately 25 to 40 years)
  • Lithium therapy
    (15% of patients who are on chronic lithium for more than 10 years)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How does Lithium Cause HPT

A
  • decreases the parathyroid cells’ sensitivity to calcium and alters the calcium set point for PTH secretion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Mostly Sporadic or ?

A
  • Primary HPT is most commonly a sporadic disease.
  • In approximately 3% to 5% of patients
    » primary HPT occurs as part of a familial syndrome including :
    -MEN1
    -MEN2A
    -MEN4
    -HPT-jaw tumor syndrome (HPT-JT)
    -familial isolated HPT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Inherited HPT

A

1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Inherited HPT

A

2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Manifestation

A

osteoporosis
nephrolithiasis
hypercalciuria
Fragility fractures
polyuria, polydipsia, renal insufficiency
Easy fatigability, generalized weakness
constipation, abdominal pain
depression, anxiety
shortened QT interval, left ventricular hypertrophy,
Heart Block

Osteopenia/osteoporosis :
Cortical bone > trabecular bone (distal third of radius most affected)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Up to 80% Diagnosed

A

Up to 80% of patients with primary HPT are diagnosed as a result of incidental hypercalcemia found on routine bloodwork.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Diagnosis and Evaluation

A
  • serum total calcium
  • intact PTH
  • creatinine
  • 25(OH)D levels
  • Serum phosphorus
  • alkaline phosphatase
  • 24-hour urine calcium and creatinine levels may also be of value.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

In a patient with hypercalcemia, if the PTH level is greater than 25 pg/mL, primary HPT remains a consideration.

A

These patients should be asked about biotin supplementation, which should be stopped a few weeks prior to PTH testing, as biotin can falsely lower PTH test results

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What can cause more sever bone disease

A

vitamin D deficiency is associated with more significant hypercalcemia, more severe bone disease, and increased parathyroid adenoma weight

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Why do RFT ?

A
  • blood urea nitrogen, serum creatinine, and glomerular filtration rate (GFR) is essential because renal insufficiency is a known complication of primary HPT and to rule out chronic kidney disease,
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Why 24 urine ?

A

A 24-hour urine calcium and creatinine measurements are checked to evaluate for
» elevated urine calcium greater than 400 mg
» which is associated with an increased risk of nephrolithiasis
» help rule out FHH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Patients with FHH have a 24-hour urine calcium less than

A

100 mg

AND

calcium creatinine clearance ratio (CCCR) less than 0.01

calculating CCCR to differentiate FHH from primary HPT should not be prioritized in the workup of primary HPT unless there is high clinical suspicion of FHH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Variants of primary HPT

A
  • Normocalcemic primary HPT
    An ionized calcium level should be obtained in all patients with suspected normocalcemic primary HPT
  • Normohormonal primary HPT :
    hypercalcemia and normal but inappropriately high intact PTH levels (>30 pg/mL).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Normal Ca and High PTH

A

other causes for an increased PTH level should be investigated, including :
-vitamin D deficiency
-renal insufficiency
-primary hypercalciuria
-malabsorption syndromes
-medications such as bisphosphonates and denosumab

18
Q

When to Check CCCR

A

If urine calcium <100 mg/24 hours

> > calculate CCCR

CCCR = (24-hour calcium urine/calcium serum)/(24-hour creatinine urine/creatinine serum)

CCCR < 0.01 → strongly suggests FHH
CCCR > 0.02 → favors primary hyperparathyroidism (PHPT)

19
Q

Genetic Testing Indications

A

Patients with pHPT less than 40 years with multigland disease

patients with a family history of pHPT or syndromes associated with pHPT

20
Q

indications for parathyroidectomy in patients with primary hyperparathyroidism.

A
  • All symptomatic patients
  • Serum calcium >1 mg/dL above the upper limit of normal
  • Age <50 years
  • BMD T score <-2.5 (osteoporosis) or significant reduction in BMD
  • Vertebral compression fracture on spine imaging
  • Impaired renal function with GFR <60 mL/min
  • Nephrolithiasis or nephrocalcinosis
  • Hypercalciuria with increased stone risk (urine calcium >400 mg/24 hours)
  • When active surveillance and routine long-term follow-up is not a good option
21
Q

All patients with primary HPT should undergo bone mineral density measurement

A

> > with dual-energy x-ray absorptiometry.

> > osteopenia = T score of –1.0 to –2.5
osteoporosis = T score of less than –2.5.

> > The distal third of the radius is most significantly affected by primary HPT, which is cortical bone.

> > The lumbar spine, which is primarily trabecular bone, is the least affected

22
Q

Parathyroid Localization

A
  • Negative imaging studies do not alter the recommendation for surgical exploration.
  • In a recent study, surgical cure was achieved in greater than 97% of patients with nonlocalizing preoperative studies, despite a greater incidence of multigland disease and requirement for more extensive surgery.
23
Q

4D CT

A

Has noncontrast phase, early arterial and delayed

Image Findings :
- peaked enhancement in arterial phase and washout in venous phase

Advantage :
more successful in localizing small adenomas and multigland disease

Limitation:
Contrast Use

24
Q

Sestamibi-SPECT

A

Image findings:
Increased focal uptake and prolonged retention of the technetium-99m sestamibi

Advantage :
Detects ectopic and posterior glands; lower radiation than 4D-CT, operator-independent

Limitation:
decreased sensitivity for multigland disease and small glands

25
US ?
Findings: -round or oval hypoechoic mass with a well-defined hypervascular echogenic capsule -typically located posterior to the superior or inferior pole of the lobe of the thyroid gland The disadvantages: -inability to detect ectopic parathyroid glands in the mediastinum, retropharyngeal, or retroesophageal locations and its decreased sensitivity in multigland disease
26
IOPTH
>> improves cure rates in patients with primary HPT and well-localized disease >> (1) preincision >> (2) preexcision >> (3) 5 minutes after gland removal >> (4) 10 minutes after gland removal Based on the Miami Criteria, a more than 50% decline in PTH at 10 minutes following parathyroid gland removal compared to the highest baseline level, either the preincision or preexcision, suggests cure and the procedure can be terminated
27
Dual criteria ??
>> are commonly used to decide when to stop parathyroid exploration >> which requires a more than 50% PTH decrease from the preincision level plus a final PTH that is within the normal range.
28
If after 10 minutes still no drop
- Additional PTH levels may be obtained if the 10-minute PTH level does not decline by more than 50% or does not fall into the normal range as expected (at 15 or 20 minutes after gland excision) and/or after further dissection and other gland(s) excision is carried out.
29
Indications for a bilateral exploration
high suspicion of multigland disease (secondary and tertiary HPT lithium-induced HPT familial HPT and discordant or negative preoperative localization studies.
30
Ectopic locations should be evaluated when an abnormal parathyroid gland cannot be identified
>> The most common ectopic location for a missing inferior gland is in the thymus >> Other ectopic sites for a missing inferior gland are the thyrothymic ligament the anterior superior mediastinum the aortopulmonary window undescended in a submandibular location the carotid sheath intrathyroidal
31
The most common ectopic location for a missing superior parathyroid gland
>> is in the tracheoesophageal groove. >> Other ectopic sites for a missing superior parathyroid gland include retroesophageal retropharyngeal the posterior mediastinum intrathyroidal
32
If all four glands appear to be abnormal
>> subtotal parathyroidectomy is performed >> remnant should be fashioned prior to removal of the remaining glands marked with a surgical clip rechecked for viability prior to removing the other parathyroid glands >> A transcervical thymectomy is also performed because the thymus is the most common site for a supernumerary parathyroid gland
33
Because parathyroid tissue can resemble fat, lymph nodes, thyroid tissue, or thymus
intraoperative identification can be confirmed with frozen section analysis or rarely by ex vivo aspiration and PTH measurement. Aspiration is performed by taking a small amount of parathyroid tissue with a fine needle and rinsing it into 1 cc of normal saline, followed by measuring PTH in the sample.
34
intraoperative adjunct to help improve parathyroid gland visualization
indocyanine green dye and near-infrared autofluorescence ultrasound bilateral jugular venous sampling radio-guided parathyroidectomy using a gamma probe.
35
During parathyroid surgery, meticulous dissection should be carried out to prevent disruption of the capsule of an abnormal parathyroid gland
can lead to parathyromatosis multiple parathyroid implants in the soft tissue of the neck Cause chronic intractable hypercalcemia
36
If a normal parathyroid gland is devascularized
>> it should be autotransplanted in the ipsilateral sternocleidomastoid muscle, a strap muscle, or the forearm and its location marked with clips for future identification.
37
cure of primary HPT
defined as eucalcemia at 6 months after surgery.
38
Patients with primary HPT who do not undergo parathyroidectomy
annual measurements of serum calcium, creatinine, and GFR. Bone mineral density should be monitored every 1 to 2 years at the spine, hip, and forearm. Vertebral fracture evaluation reevaluation for kidney stones Hydration should be encouraged to prevent progression of hypercalcemia and nephrolithiasis
39
Cinacalcet
an allosteric activator of the CaSR, and has been used for treatment of hypercalcemia in patients with recurrent or metastatic parathyroid cancer, hypercalcemic crisis (HC), and secondary HPT. It sensitizes the CaSR to serum calcium approved by the FDA for patients with severe primary HPT who are unable to undergo surgery cinacalcet has no effect on bone loss
40
Bisphosphonate
- used to improve bone mass in patients with primary HPT and osteoporosis. - Bisphosphonates do not change calcium or PTH levels
41
In patients with primary HPT who require both a reduction in serum calcium levels and improvement in bone mineral density but cannot undergo parathyroidectomy
the combination of cinacalcet and bisphosphonate therapy
42
Thiazide diuretics
used to decrease the urine calcium levels in patients with primary HPT and hypercalciuria, which can reduce the risk of calcium stone disease